Teladoc, Inc. (TDOC) Receives Average Recommendation of “Buy” from Analysts
Shares of Teladoc, Inc. (NYSE:TDOC) have received a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $38.00.
Several research firms have issued reports on TDOC. BidaskClub raised Teladoc from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 price objective on shares of Teladoc in a report on Friday, July 28th. KeyCorp reaffirmed a “buy” rating and set a $37.00 price objective on shares of Teladoc in a report on Sunday, September 17th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $31.00 price objective on shares of Teladoc in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st.
Teladoc (TDOC) opened at 32.00 on Thursday. Teladoc has a 12 month low of $14.00 and a 12 month high of $37.55. The firm’s market capitalization is $1.81 billion. The stock’s 50 day moving average price is $33.27 and its 200 day moving average price is $33.27.
Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm’s revenue was up 68.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.38) earnings per share. Equities research analysts expect that Teladoc will post ($1.46) earnings per share for the current fiscal year.
In other Teladoc news, VP Mark Hirschhorn sold 25,000 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $31.93, for a total transaction of $798,250.00. Following the completion of the sale, the vice president now owns 64,987 shares in the company, valued at approximately $2,075,034.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Adam C. Vandervoort sold 53,806 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. Insiders have sold a total of 168,806 shares of company stock valued at $5,430,382 in the last quarter. Corporate insiders own 4.47% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. raised its position in shares of Teladoc by 125.7% during the 1st quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock valued at $3,288,000 after acquiring an additional 73,231 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Teladoc by 22.2% during the 2nd quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after acquiring an additional 507,390 shares during the last quarter. Swiss National Bank raised its position in shares of Teladoc by 37.5% during the 1st quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock valued at $1,420,000 after acquiring an additional 15,500 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Teladoc during the 2nd quarter valued at $58,287,000. Finally, Riverbridge Partners LLC bought a new stake in shares of Teladoc during the 2nd quarter valued at $23,392,000.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.